877160-63-9 Usage
General Description
4-Amino-2-chlorophenylboronic acid, pinacol ester is a chemical compound consisting of a boronic acid group, an amino group, and a chlorine atom attached to a phenyl ring. The pinacol ester group is attached to the boronic acid, making it a stable and easy-to-handle form of the compound. This chemical is often used in organic synthesis as a building block for pharmaceuticals, agrochemicals, and materials science. It is a versatile reagent in Suzuki-Miyaura cross-coupling reactions, allowing for the formation of carbon-carbon bonds between aryl and heteroaryl compounds. The pinacol ester moiety also provides protection for the boronic acid functionality, making it more stable and easier to handle in various chemical reactions.
Check Digit Verification of cas no
The CAS Registry Mumber 877160-63-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,7,1,6 and 0 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 877160-63:
(8*8)+(7*7)+(6*7)+(5*1)+(4*6)+(3*0)+(2*6)+(1*3)=199
199 % 10 = 9
So 877160-63-9 is a valid CAS Registry Number.
InChI:InChI=1/C12H17BClNO2/c1-11(2)12(3,4)17-13(16-11)9-6-5-8(15)7-10(9)14/h5-7H,15H2,1-4H3
877160-63-9Relevant articles and documents
PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS
-
Paragraph 0142; 0143; 0144, (2021/03/05)
Provided herein are compounds of formula (I) as shown below, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
PERK INHIBITING COMPOUNDS
-
Paragraph 0135-0137, (2021/03/05)
Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.
PERK INHIBITORS FOR TREATING VIRAL INFECTIONS
-
Page/Page column 66; 67, (2021/11/20)
Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I):